We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Inotiv Inc | NASDAQ:NOTV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.73% | 1.76 | 1.71 | 2.52 | 1.82 | 1.72 | 1.74 | 149,749 | 05:00:07 |
Robert Leasure, Jr., Inotiv’s President and Chief Executive Officer, commented, “In laying the groundwork for Inotiv’s 2024 strategic operating plan, we continue to effectively execute across our planned initiatives. Leveraging the broad range of products and services we can now offer, we are positioning our commercial organization to increase sales volume through greater cross-selling to our existing customers, in addition to establishing relationships with new customers. As the majority of Inotiv’s site optimization plan has largely been completed which has included the closure of 11 sites and investments in existing sites, along with opening new Discovery and Safety Assessment sites and adding complementary service offerings, we believe these investments expand our range of services, generate revenue growth, increase margins, improve our ability to recruit and retain talent and produce positive returns for our shareholders. We look forward to updating shareholders on our operations and reporting fourth quarter and full year fiscal 2023 audited results shortly, along with commentary on our balance sheet and cash flows.”
Business and Operational Updates
The Company will be participating in the following investor conferences that will be webcast in November 2023:
Event: Jefferies London Healthcare ConferenceLocation: London, United KingdomPresentation Date: November 15, 2023Time: 4:00 PM Greenwich Mean Time
Event: 6th Annual Evercore ISI HealthCONx ConferenceLocation: Miami, FLPresentation Date: November 29, 2023Time: 3:00 PM Eastern TimeLink to Webcast
The webcast presentations will be available for viewing and replay under the “Investor Relations” tab of the Company's website at www.inotivco.com.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, Company’s ability to reduce its legal and third party fees, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims, investigations and litigation against or involving the Company, its business and/or its industry, the expected timing and impact, including on operations, expenses and other results, of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Company Contact | Investor Relations | |
Inotiv, Inc. | LifeSci Advisors | |
Beth A. Taylor, Chief Financial Officer | Bob Yedid | |
(765) 497-8381 | (516) 428-8577 | |
btaylor@inotivco.com | bob@lifescieadvisors.com | |
1 Year Inotiv Chart |
1 Month Inotiv Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions